England’s medical cannabis market has barely gotten off the ground since launching about 19 months ago, with a two-tier system in which few patients access products through legal channels while most resort to illicit suppliers.
Doctors in New Zealand no longer require Ministry of Health approval to prescribe Sativex, according to a new notice published in the country’s official Gazette – a move that could facilitate access to the pharmaceutical-grade, cannabis-based product.
The U.S. Food and Drug Administration is approving a growing number of applications from cannabis companies looking to conduct clinical trials studying medical marijuana. That development could lead to multiple cannabis-based medicines—including flower—receiving FDA approval to be commercialized and sold within the next five years.
A popular cannabis-derived epilepsy treatment is increasing sales for a London company making pharmaceutical treatments from marijuana.
As CEO of Bryant Park Capital, a New York-based investment bank that provides services to both the cannabis and traditional investment banking markets, Joel Magerman sees cannabis companies showing increased business discipline. And this, he said, is good news for all parties involved.
